secwatch.observer — SEC 8-K summary
======================================

Issuer:     Danimer Scientific, Inc. (—)
CIK:        0001779020
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038004
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Danimer reports FY2023 revenue down 12% to $46.7M; guides FY2024 Adj. EBITDA improvement
--------------------------------------------------------------------------------

- Q4 revenue $10.9M (-29% YoY); full-year revenue $46.7M vs $53.2M.
- Full-year Adj. EBITDA $(39.0)M vs $(45.0)M in 2022; Q4 Adj. EBITDA $(10.7)M.
- FY2024 Adj. EBITDA guidance $(22)-(32)M; CapEx $8-10M; expects accelerating H2 growth.
- Unrestricted cash $59.2M at Dec 31, 2023; March 2024 equity raise added >$13M.
- PHA sales grew 6% YoY; PLA sales declined $6.1M due to Ukraine conflict.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1779020/000095017024038004/0000950170-24-038004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1779020/000095017024038004/dnmr-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer